115 related articles for article (PubMed ID: 121645)
1. Effects of the sulphonylurea drugs gliclazide and glibenclamide on blood glucose control and platelet function.
Klaff LJ; Vinik AI; Jackson WP; Malan E; Kernoff L; Jacobs P
S Afr Med J; 1979 Aug; 56(7):247-50. PubMed ID: 121645
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of the effects of some sulphonylureas on platelet function.
King JB; Kalk WJ; Vinik AI; Jackson WP; Bracher M; Jacobs P
S Afr Med J; 1977 Jan; 51(5):124-6. PubMed ID: 322325
[TBL] [Abstract][Full Text] [Related]
3. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
Konya H; Hasegawa Y; Hamaguchi T; Satani K; Umehara A; Katsuno T; Ishikawa T; Miuchi M; Kohri K; Suehiro A; Kakishita E; Miyagawa J; Namba M
Metabolism; 2010 Sep; 59(9):1294-9. PubMed ID: 20070990
[TBL] [Abstract][Full Text] [Related]
4. [Effects of gliclazide and glibenclamide on platelet function, fibrinolysis and metabolic control in diabetic patients with retinopathy (author's transl)].
Chan TK; Chan V; Teng CS; Yeung RT
Sem Hop; 1982 May; 58(19):1197-200. PubMed ID: 6285503
[TBL] [Abstract][Full Text] [Related]
5. Sulfonylureas and platelet function.
Klaff LJ; Kernoff L; Vinik AI; Jackson WP; Jacobs P
Am J Med; 1981 Mar; 70(3):627-30. PubMed ID: 6782875
[TBL] [Abstract][Full Text] [Related]
6. Effects of diet and gliclazide on the haemostatic system of non-insulin-dependent diabetics.
Paton RC; Kernoff PB; Wales JK; McNicol GP
Br Med J (Clin Res Ed); 1981 Oct; 283(6298):1018-20. PubMed ID: 6794745
[TBL] [Abstract][Full Text] [Related]
7. The inhibition of cancer cell stickiness, a model for investigation of platelet aggregation inhibitors in vivo. Effect of the sulfonyl urea derivatives, glibenclamide, gliclazide, and HB180, as well as the carboxylic acid derivative, meglitinide.
Gastpar H; Weissgerber PW; Enzmann F; Zoltobrocki M
Res Exp Med (Berl); 1982; 180(1):75-84. PubMed ID: 6805052
[TBL] [Abstract][Full Text] [Related]
8. [Free radical scavenging activity of sulfonylureas: a clinical assessment of the effectiveness of gliclazide].
Jennings PE; Belch JJ
Ter Arkh; 2001; 73(4):27-31. PubMed ID: 11494442
[TBL] [Abstract][Full Text] [Related]
9. Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: a two-year controlled study.
Larkins RG; Jerums G; Taft JL; Godfrey H; Smith IL; Martin TJ
Diabetes Res Clin Pract; 1988 Jan; 4(2):81-7. PubMed ID: 3125029
[TBL] [Abstract][Full Text] [Related]
10. The effects of gliclazide on platelet function in patients with diabetes mellitus.
Violi F; De Mattia GC; Alessandri C; Perrone A; Vezza E
Curr Med Res Opin; 1982; 8(3):200-3. PubMed ID: 7128193
[TBL] [Abstract][Full Text] [Related]
11. Antiaggregatory activity of hypoglycaemic sulphonylureas.
Siluk D; Kaliszan R; Haber P; Petrusewicz J; Brzozowski Z; Sut G
Diabetologia; 2002 Jul; 45(7):1034-7. PubMed ID: 12136403
[TBL] [Abstract][Full Text] [Related]
12. [Long-term effect of gliclazide on platelet function in diabetes].
Pan CY
Zhonghua Yi Xue Za Zhi; 1984 Apr; 64(4):233-5. PubMed ID: 6432285
[No Abstract] [Full Text] [Related]
13. Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.
Holmes B; Heel RC; Brogden RN; Speight TM; Avery GS
Drugs; 1984 Apr; 27(4):301-27. PubMed ID: 6373223
[TBL] [Abstract][Full Text] [Related]
14. Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes.
Baba S; Nakagawa S; Takebe K; Goto Y; Maezawa H; Takeda R; Sakamoto N; Fukui I
Tohoku J Exp Med; 1983 Dec; 141 Suppl():693-706. PubMed ID: 6440313
[TBL] [Abstract][Full Text] [Related]
15. [Hemorheologic, metabolic and blood coagulation changes in diabetics in treatment with sulfanyl ureas].
Cortinovis A; Crippa A; Sciacca V; Caravaggio V; Crippa M
Minerva Med; 1988 May; 79(5):391-8. PubMed ID: 3131696
[TBL] [Abstract][Full Text] [Related]
16. The potentiating effect of the simultaneous administration of tolbutamide, glibenclamide, and gliclazide on the development of alloxan-induced diabetes in rats.
Katsumata K; Katsumata Y
Horm Metab Res; 1990 Jan; 22(1):51-2. PubMed ID: 2106472
[No Abstract] [Full Text] [Related]
17. Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients.
Wascher TC; Boes U
Clin Physiol Funct Imaging; 2005 Jan; 25(1):40-6. PubMed ID: 15659079
[TBL] [Abstract][Full Text] [Related]
18. The in vivo interaction between gliclazide and glibenclamide and insulin on glucose disposal in the rat.
Tanira MO; Furman BL
Pharmacol Res; 1999 May; 39(5):349-56. PubMed ID: 10328992
[TBL] [Abstract][Full Text] [Related]
19. [Does hypoglycemic treatment with gliclazide and gliquidone affect platelet function in type II diabetic patients?].
Strojek K; Bresler M; Gumprecht J; Grzeszczak W; Trautsolt W
Pol Arch Med Wewn; 1993 Apr; 89(4):315-9. PubMed ID: 8351232
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus--an effect probably mediated by direct platelet PPARgamma activation.
Khanolkar MP; Morris RH; Thomas AW; Bolusani H; Roberts AW; Geen J; Jackson SK; Evans LM
Atherosclerosis; 2008 Apr; 197(2):718-24. PubMed ID: 17765245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
